Integrative analysis and refined design of CRISPR knockout screens
暂无分享,去创建一个
Han Xu | Clifford A. Meyer | Myles Brown | X. Shirley Liu | Tengfei Xiao | Peng Jiang | Chen-Hao Chen | Wei Li | X. Liu | Han Xu | Wei Li | Peng Jiang | T. Xiao | Chenhao Chen | Myles A. Brown | X. Liu | Peng Jiang | X. Liu
[1] Jun S. Liu,et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR , 2015, Genome Biology.
[2] J. Doudna,et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.
[3] Matthew C. Canver,et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis , 2015, Nature.
[4] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[5] David A. Orlando,et al. Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. , 2014, Cell reports.
[6] R. Barrangou,et al. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.
[7] E. Crawford,et al. Characterising the castration‐resistant prostate cancer population: a systematic review , 2011, International journal of clinical practice.
[8] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[9] Tim J. Wigle,et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.
[10] R. Terns,et al. Cas9 function and host genome sampling in Type II-A CRISPR–Cas adaptation , 2015, Genes & development.
[11] D. Morgens,et al. Systematic comparison of CRISPR-Cas9 and RNAi screens for essential genes , 2016, Nature Biotechnology.
[12] H. Xiang,et al. Adaptation of the Haloarcula hispanica CRISPR-Cas system to a purified virus strictly requires a priming process , 2013, Nucleic acids research.
[13] R. Mehra,et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. , 2012, Cancer research.
[14] H. Lepor,et al. Androgen deprivation therapy in the treatment of advanced prostate cancer. , 2007, Reviews in urology.
[15] Bin Li,et al. A new class of temporarily phenotypic enhancers identified by CRISPR/Cas9-mediated genetic screening , 2016, Genome research.
[16] H. Hieronymus,et al. Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.
[17] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[18] J. García-Martínez,et al. Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements , 2005, Journal of Molecular Evolution.
[19] F. Rodríguez-Valera,et al. Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning , 1995, Molecular microbiology.
[20] T. Thompson,et al. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches , 2013, Oncogene.
[21] R. Tjian,et al. Dynamics of CRISPR-Cas9 genome interrogation in living cells , 2015, Science.
[22] Stan J. J. Brouns,et al. Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes , 2008, Science.
[23] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[24] B. Li,et al. Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.
[25] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[26] M. Henry,et al. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? , 2011, Nature Reviews Urology.
[27] D van Soolingen,et al. Insertion element IS987 from Mycobacterium bovis BCG is located in a hot-spot integration region for insertion elements in Mycobacterium tuberculosis complex strains , 1991, Infection and immunity.
[28] F. Stegmeier,et al. Abstract B21: CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions , 2017 .
[29] G. Church,et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.
[30] Luciano A. Marraffini,et al. Cas9 specifies functional viral targets during CRISPR-Cas adaptation , 2015, Nature.
[31] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[32] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[33] Jun S. Song,et al. HiTSelect: a comprehensive tool for high-complexity-pooled screen analysis , 2014, Nucleic acids research.
[34] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[35] E. Lander,et al. Identification and characterization of essential genes in the human genome , 2015, Science.
[36] Zhongzheng Cao,et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR–Cas9 library , 2016, Nature Biotechnology.
[37] T. Golub,et al. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. , 2016, Cancer discovery.
[38] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[39] R. Elkon,et al. Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9 , 2016, Nature Biotechnology.
[40] T. Guthrie,et al. Prostate cancer. , 2020, American family physician.
[41] Chun Jimmie Ye,et al. A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks , 2015, Cell.
[42] J. Moffat,et al. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics , 2014, Molecular systems biology.
[43] E. Lander,et al. Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.
[44] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[45] Jun S. Liu,et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.
[46] Morten Nielsen,et al. Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion , 2012, Nucleic Acids Res..
[47] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[48] Shiyou Zhu,et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells , 2014, Nature.
[49] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[50] Jon C. Aster,et al. Network analysis of gene essentiality in functional genomics experiments , 2015, Genome Biology.
[51] Damian Szklarczyk,et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration , 2012, Nucleic Acids Res..
[52] Philippe Horvath,et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA , 2010, Nature.
[53] M. Vetter,et al. PRC2 during vertebrate organogenesis: a complex in transition. , 2012, Developmental biology.
[54] S. Ehrlich,et al. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. , 2005, Microbiology.
[55] M. Loda,et al. EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.
[56] J. Moffat,et al. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics , 2014, bioRxiv.
[57] Clifford A. Meyer,et al. Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.
[58] L. Schouls,et al. Identification of genes that are associated with DNA repeats in prokaryotes , 2002, Molecular microbiology.
[59] Stan J. J. Brouns,et al. CRISPR Interference Directs Strand Specific Spacer Acquisition , 2012, PloS one.
[60] J. Keith Joung,et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.
[61] R. König,et al. A probability-based approach for the analysis of large-scale RNAi screens , 2007, Nature Methods.
[62] Sven Laur,et al. Robust rank aggregation for gene list integration and meta-analysis , 2012, Bioinform..
[63] Qingzhong Hu,et al. CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents , 2014, Nature Reviews Urology.
[64] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[65] Rameen Beroukhim,et al. An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.
[66] N. Hacohen,et al. Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.
[67] D. Durocher,et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.
[68] J. Licht,et al. Epigenetic therapy of hematological malignancies: where are we now? , 2013, Therapeutic advances in hematology.
[69] M. Dawson,et al. Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.
[70] L. Marraffini,et al. Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site , 2011, Proceedings of the National Academy of Sciences.
[71] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[72] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[73] Meagan E. Sullender,et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.
[74] Eli J. Fine,et al. DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.
[75] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[76] G. Calin,et al. Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.
[77] Jiyang Yu,et al. ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling , 2015, Bioinform..
[78] T. Kanda,et al. Identification of an Insulator in AAVS1, a Preferred Region for Integration of Adeno-Associated Virus DNA , 2003, Journal of Virology.
[79] Darren J. Wilkinson,et al. Bayesian methods in bioinformatics and computational systems biology , 2006, Briefings Bioinform..
[80] P. Linsley,et al. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.
[81] Joshua M. Korn,et al. CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions. , 2016, Cancer discovery.
[82] C. Daniel,et al. Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer , 2012, Nature Reviews Drug Discovery.
[83] Martin J. Aryee,et al. GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.
[84] L. Marraffini,et al. CRISPR Interference Limits Horizontal Gene Transfer in Staphylococci by Targeting DNA , 2008, Science.
[85] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[86] J. Trapman,et al. The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.
[87] Lei Zhang,et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. , 2010, Genome research.
[88] Debashis Ghosh,et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[89] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[90] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[91] R. Ketting. The many faces of RNAi. , 2011, Developmental cell.
[92] E. Chan,et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. , 2013, Chemistry & biology.
[93] Juri Rappsilber,et al. A model for transmission of the H3K27me3 epigenetic mark , 2008, Nature Cell Biology.
[94] H. Scher,et al. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. , 2014, Oncology.
[95] Clifford A. Meyer,et al. Sequence determinants of improved CRISPR sgRNA design , 2015, Genome research.
[96] M. Lomax,et al. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[97] P. Atadja,et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.
[98] A. Chase,et al. Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.
[99] Meagan E. Sullender,et al. Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation , 2014, Nature Biotechnology.
[100] Jong-il Kim,et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells , 2015, Nature Methods.
[101] Yilong Li,et al. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.
[102] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[103] M. Lübbert,et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy , 2010, Clinical Epigenetics.
[104] Michel Sadelain,et al. Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.
[105] Yong Jiang,et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.